Literature DB >> 1359120

Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1).

Y Tanigawara1, N Okamura, M Hirai, M Yasuhara, K Ueda, N Kioka, T Komano, R Hori.   

Abstract

This article represents the first evidence that the renal secretion of the commonly used drug, digoxin, is mediated by P-glycoprotein. In this study, it was demonstrated that digoxin is a substrate of P-glycoprotein, and the mechanism of a clinically important drug interaction, such as digoxin-quinidine, was elucidated. Human P-glycoprotein was expressed on the apical membrane of the porcine kidney epithelial cell line, LLC-PK1 by transfecting with human MDR1 cDNA. The expression and function of P-glycoprotein were confirmed by Southern and Western blotting, RNase protection assay, immunostaining and transporting activity for vinblastine. The transepithelial transport of [3H]digoxin was measured across the cell monolayers grown on microporous polycarbonate membrane filters. The transfectant cells exhibited markedly greater basal-to-apical transport and less apical-to-basal transport than the host cells, and the former was 8-fold greater than the latter. The augmented transepithelial transport resulted from the increased efflux from cells to apical side. This oriented transport was inhibited by the presence of 20 microM vinblastine, quinidine or verapamil. The rate of efflux to the apical side was 2-fold greater than that to the basal side. Quinidine inhibited the efflux to the apical side but did not affect transport into the basal side. These findings demonstrate that digoxin is transported by human P-glycoprotein, which is a previously undiscovered drug transport system in the kidney other than organic cation and anion transport systems, and suggest a molecular mechanism for the renal tubular secretion of digoxin as well as clinically important digoxin-quinidine interaction via P-glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359120

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  56 in total

1.  MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects.

Authors:  T Sakaeda; T Nakamura; M Horinouchi; M Kakumoto; N Ohmoto; T Sakai; Y Morita; T Tamura; N Aoyama; M Hirai; M Kasuga; K Okumura
Journal:  Pharm Res       Date:  2001-10       Impact factor: 4.200

Review 2.  Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin.

Authors:  J F Westphal
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

Review 3.  Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders.

Authors:  Gloria Lee; Reina Bendayan
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

4.  Modification of the P-glycoprotein dependent pharmacokinetics of digoxin in rats by human recombinant interferon-alpha.

Authors:  Makrem Ben Reguiga; Laurence Bonhomme-Faivre; Simone Orbach-Arbouys; Robert Farinotti
Journal:  Pharm Res       Date:  2005-08-16       Impact factor: 4.200

5.  Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux.

Authors:  Yoko Honda; Fumihiko Ushigome; Noriko Koyabu; Satoshi Morimoto; Yukihiro Shoyama; Takeshi Uchiumi; Michihiko Kuwano; Hisakazu Ohtani; Yasufumi Sawada
Journal:  Br J Pharmacol       Date:  2004-10-25       Impact factor: 8.739

6.  Evaluation of a Potential Clinical Significant Drug-Drug Interaction between Digoxin and Bupropion in Cynomolgus Monkeys.

Authors:  Yang Shen; Yang Yu; Wei Lai; Shuai Li; Zixuan Xu; Jiejing Jin; Xia Yan; Han Xing; Xijing Chen; Aizhen Xiong; Chunhua Xia; Jiake He; Kui Hong
Journal:  Pharm Res       Date:  2018-11-06       Impact factor: 4.200

Review 7.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Common single nucleotide polymorphisms of the MDR1 gene have no influence on its mRNA expression level of normal kidney cortex and renal cell carcinoma in Japanese nephrectomized patients.

Authors:  Yuichi Uwai; Satohiro Masuda; Maki Goto; Hideyuki Motohashi; Hideyuki Saito; Masahiro Okuda; Eijirou Nakamura; Noriyuki Ito; Osamu Ogawa; Ken-Ichi Inui
Journal:  J Hum Genet       Date:  2003-12-18       Impact factor: 3.172

9.  Enhancing the anticancer properties of cardiac glycosides by neoglycorandomization.

Authors:  Joseph M Langenhan; Noël R Peters; Ilia A Guzei; F Michael Hoffmann; Jon S Thorson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-16       Impact factor: 11.205

10.  Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction.

Authors:  Jens Rengelshausen; Christoph Göggelmann; Jürgen Burhenne; Klaus-Dieter Riedel; Jochen Ludwig; Johanna Weiss; Gerd Mikus; Ingeborg Walter-Sack; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.